Nilemdo (Bempedoic Acid)

Bempedoic acid inhibits the enzyme ATP‑citrate lyase, which lies upstream of HMG‑CoA reductase in the hepatic cholesterol synthesis pathway. Blocking this enzyme reduces the production of cholesterol in the liver, prompting an increase in LDL‑receptor expression and enhanced clearance of LDL particles from the bloodstream, thereby lowering circulating LDL‑cholesterol levels.

The appropriate dose of Nilemdo is determined by the prescribing physician based on clinical guidelines, the patient’s lipid profile, concomitant statin therapy, and individual health factors. Healthcare providers select the dose that best balances efficacy with safety for each patient.

Safety data for bempedoic acid in pregnancy and lactation are limited. The drug should be avoided unless the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative lipid‑lowering strategies with their healthcare professional.

To request Nilemdo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. The sales team then replies with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Nilemdo works upstream of statins by inhibiting ATP‑citrate lyase, offering an additive LDL‑C reduction when combined with maximally tolerated statins. Unlike PCSK9 inhibitors, it is an oral small‑molecule therapy, which may be preferred for patients seeking a non‑injectable option. Its safety profile differs, with a lower incidence of muscle‑related side effects than high‑dose statins but a unique risk of tendon rupture and elevated uric acid.

Nilemdo should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and avoid storing it in areas with high humidity or temperature fluctuations to maintain potency.

Nilemdo is taken orally, typically once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious adverse events associated with Nilemdo include tendon rupture, severe liver injury (marked elevations in ALT/AST with possible jaundice), and hypersensitivity reactions such as rash, angioedema or anaphylaxis. Patients should seek immediate medical attention if they experience sudden tendon pain, signs of liver dysfunction, or any severe allergic symptoms.

Nilemdo is contraindicated in patients with known hypersensitivity to bempedoic acid or any of its excipients, and in those with severe hepatic impairment. Caution is also advised for individuals with a history of gout or elevated uric acid, as the drug may exacerbate these conditions. Pregnant or breastfeeding women should only use it if the potential benefit justifies the risk.